Skip to main content
SpringerLink
Log in

Labelling for ibrutinib updated for risk of HBV reactivation

  • Correspondence
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Seoighe B. IMBRUVICA (ibrutinib) and risk of hepatitis B reactivation: hepatitis B virus status to be established before initiating treatment with IMBRUVICA. Internet Document : [2 pages], 17 Jul 2017. Available from: URL: http://www.hpra.ie/docs/default-source/Safety-Notices/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Labelling for ibrutinib updated for risk of HBV reactivation. Reactions Weekly 1662, 4 (2017). https://doi.org/10.1007/s40278-017-33634-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-33634-1

Search

Navigation